e11524 Background: Neoadjuvant Rx has been shown to downstage locally advanced breast cancer (LABC) to try to achieve a pathological complete response(PCR) and to convert mastectomy to lumpectomy. Bevacizumab (B) was recently approved to treat metastatic breast cancer in combination with paclitaxel (P). NSABP B-27 used preoperative doxorubicin(A) with cyclophosphamide (C) +- docetaxel (Doc) every 3 wks in primary operable breast cancer, yielding a 12.9% PCR with no residual invasive cancer from AC and 26.1% with the addition of Doc. Based on the success of E2100 with P+B over P, and the more recent AVADO trial showing the superiority of B and Doc over Doc, we have treated such Her2neu-neg pts using Doc/B followed by AC/B with a dose dense every (q) 2 week regimen to see if we could achieve a higher PCR rate and to assess the tolerability of this regimen. Methods: Pts with Her2neu-negative locally advanced operable M0 breast cancer were treated initially with B 10mg/kg iv q 2w with Doc 100mg/m2 q 2w four times with pegfilgrastim given 24 hours after chemotherapy, followed by A 60mg/m2 and C 600mg/m2 q 2 weeks four 4 times with pegfilgrastim given 24 hours after chemotherapy with B 10mg/kg iv for the first AC course as the B was discontinued at least 6 weeks prior to definitive breast surgery. All pts were to get radiation therapy after surgery and appropriate anti-estrogen Rx if estrogen receptor was positive. Results: 15 Her-2 neg women aged 35–61 were treated from 9/06-present for locally advanced primary operable breast cancer. All pts had clinically significant tumor reduction. Of the first 12 post-operative evaluable pts that have completed all the pre- operative therapy, the results showed 5 PCR, including one pt with residual sub-cm DCIS, 7 pathological incomplete responses, yielding a 42% PCR. 3 of the 5 PCR pts had lumpectomies. The major toxicity was excessive eye tearing, nail bed changes and lethargy. Conclusions: This novel dose dense q 2 week regimen is safe, tolerable and effective in LABC with acceptable toxicity. The addition of B to dose dense traditional neoadjuvant chemotherapy seems to increase the PCR. Larger prospective trials using B with dose dense therapy are warranted. No significant financial relationships to disclose.